http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
HCT116 대장암 세포주에서 Butyrate에 의한 Survivin 발현 변화
박동국(Dong-Guk Park) 대한외과학회 2009 Annals of Surgical Treatment and Research(ASRT) Vol.77 No.5
Purpose: The causes of colon cancer can be divided into genetic and environmental components. A high-fiber diet is known to reduce the risk of colon cancer. Dietary fiber is converted to short chain fatty acid, butyrate, in the colon by bacteria. Butyrate is used as an energy source for the colonic epithelial cells, and is known to induce apoptosis in colon cancer cell lines. Survivin, a recently discovered member of the IAP (inhibitor of apoptosis) family, is known to suppress apoptosis. Not only does it suppress cell apoptosis, but it also has a protective effect from disabling G2/M phase of the cell cycle by attaching to the microtubule of the mitotic spindle. The purpose of this study is to evaluate the effect of butyrate on the expression of survivin, in HCT116 colon cancer cell lines. Methods: Cytotoxicity of butyrate was measured by MTS method. Cell cycle phase and apoptosis was analyzed by flowcytometry. Protein expression of survivin was evaluated by Western blot analysis, and the mRNA expression by RT-PCR. Results: Butyrate can induce apoptosis in HCT116 colon cancer cell line at a concentration of 6 mM. Butyrate suppressed the expression of survivin mRNA and also the expression of cytosolic and nuclear survivin. In flowcytometric analysis, the apoptotic portion was increased and the proportions of S and M phase were decreased when cultured with butyrate. Conclusion: We concluded that butyrate could induce cellular apoptosis partially by suppressing the expression of survivin in HCT116 colon cancer cells.
전이성 대장암에서 FOLFOX4 항암 화학요법 시행 중 발생한 간질성 폐질환 1예
윤정석(Jeung-seuk Yoon),박동국(Dong-Guk Park),남궁환(Hwan Namgung),김도형(Doh-hyung Kim) 대한종양외과학회 2012 Korean Journal of Clinical Oncology Vol.8 No.1
FOLFOX4 요법은 진행성 대장직장암에서 첫 번째 치료 요법 중 하나이다. 잘 알려진 부작용으로 신경학적, 혈액학적, 소화기 독성이 있다. 그러나 최근 들어 이 요법과 관련된 심각한 폐독성이 보고 되고 있다. 저자들은 FOLFOX4 요법 중 발생한 간질성 폐질환 1예를 보고하는 바이다. FOLFOX4 regimen is one of the first line treatments for advanced colorectal cancer. Well known adverse effects are neurological, hematologic, and gastro-intestinal toxicities. But recently, there were several case reports about severe form pulmonary toxicity of this regimen. We herein report the case of an additional patient with FOLFOX4 induced interstitial lung disease.